NCT04202692View on ClinicalTrials.gov

Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions
Gastro Esophageal Reflux
Interventions
DEVICE

Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet

1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks

DEVICE

Placebo 1100 mg, identically-looking melt in mouth tablet

1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks

Trial Locations (2)

30459

Klinikum Region Hannover (KRH) Klinikum Siloah, Hanover

57074

Diakonie Klinikum GmbH - Jung- Stilling Krankenhaus, Siegen

All Listed Sponsors
lead

SOFAR S.p.A.

INDUSTRY

NCT04202692 - Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment | Biotech Hunter | Biotech Hunter